European Medicines Agency Committee Backs Several New Drug Approvals

The European Medicines Agency's CHMP has issued positive recommendations for several new medicines, moving them closer to market authorization in Europe. These include treatments for pancreatic cancer, diabetes, and achondroplasia. Notably, Eli Lilly's oral obesity drug, orforglipron (Foundayo), received CHMP backing for both weight management and type 2 diabetes, marking a significant step for the pharmaceutical company.